INTRODUCTION

Since Liggins and Howie
5 published their landmark study in 1972 reporting the benefit of antepartum betamethasone to enhance fetal lung maturation in women at risk for preterm delivery, potent glucocorticoids for this indication have become increasingly utilized for women at risk of delivery between 24 and 34 weeks of gestational age. An NIH Consensus Panel 8 in August 2000 concluded from the available published evidence that either betamethasone given as two doses of 12 mg intramuscularly (IM, each given 24 hours apart), or dexamethasone phosphate given as four doses of 6 mg IM (each given 12 hours apart), should be used for this indication.
During the first 3 months of 2001, many hospitals in the United States began to experience difficulty acquiring sufficient supplies of either drug to meet patient needs. This has prompted a search for an alternative medication until adequate supplies of dexamethasone and betamethasone are restored to providers and patients.
METHODS
A medline search was performed from 1966 to the present using the keyword ''antenatal steroids.'' This keyword was further mapped using the ''AND'' Boolean operator to ''glucocorticoids AND respiratory distress syndrome'' and ''glucocorticoids AND premature labor.'' Review articles were excluded as were trials using betamethasone or dexamethasone unless these drugs were used in comparison with other modalities. Randomized controlled trials were preferentially selected.
RESULTS
In the 1970s and 1980s, before the acceptance of betamethasone and dexamethasone as the drugs of choice for enhancing fetal lung maturity before delivery, several other glucocorticoids were studied. Hydrocortisone and cortisol are naturally occurring glucocorticoids. Betamethasone, dexamethasone and methylprednisolone are synthetic steroids that have been structurally engineered to enhance their glucocorticoid activity while minimizing mineralocorticoid activity. As a result, protein binding and rates of elimination for these drugs have also been changed. Following are summaries of randomized controlled studies using cortisol, hydrocortisone and methylprednisolone.
Cortisol
Whitt et al. 6 compared use of the standard betamethasone regimen to cortisol given as 1000 mg IV every 8 hours in four doses to women with preterm labor between 28 and 34 weeks' gestational age. The onset of effect in the cortisol patients appeared to occur 9 hours
OBJECTIVE:
To review the literature on alternatives to betamethasone and dexamethasone for enhancement of fetal lung maturity.
STUDY DESIGN:
A medline search was conducted from 1966 to the present. Trials dealing with enhancement of fetal lung maturity using modalities other than betamethasone or dexamethasone were reviewed.
RESULTS:
Eight studies met inclusion criteria. Excluding betamethasone and dexamethasone, the most frequently studied glucocorticoids, for fetal lung maturation, are methylprednisolone and hydrocortisone. Methylprednisolone does not cross the placenta. Two grams of hydrocortisone has been shown to improve indices of fetal lung maturity ( i.e., L / S ratio ) and to improve fetal outcomes compared to no treatment.
CONCLUSION:
There is limited information about alternatives to betamethasone and dexamethasone for the enhancement of fetal lung maturity in women at risk of preterm delivery. In the absence of these two preferred drugs, hydrocortisone can be given at a dose of 500 mg intravenously every 12 hours for four doses for this indication. 
Rapid Communication
earlier than in the betamethasone group and over time the magnitude of the effect was greater with cortisol. Steroid effect was measured indirectly by its suppression of unconjugated maternal serum estriol. The incidence of respiratory distress was negligible in both arms of the study. Limitations of this study are the small sample size (seven in each group).
Hydrocortisone
Ballard and Liggins, 1 between 1977 and 1981, studied 71 infants of women in preterm labor who received either hydrocortisone (100 mg IV initially followed by 100 mg IM every 8 hours to maximum of 400 mg) or betamethasone (12 mg IM twice, separated by 24 hours or 6 mg IM every 12 hours for four doses). Cord serum cortisol concentrations were compared among groups. The maximum serum cortisol concentration of 32 g/dl occurred 1 hour after injection of hydrocortisone, a 3.8-fold increase above baseline. The half-life of hydrocortisone was approximately 2 hours compared to 12 hours for betamethasone. Hydrocortisone produced higher concentrations of unbound cortisol than betamethasone (11.6 vs. 9.6 g/dl for the 12-mg regimen and 6.9 g/dl for the 6-mg regimen) but had a shorter duration of action (32 hours for hydrocortisone vs. 72 and 60 hours for betamethasone). No measurements of fetal-neonatal benefit or outcome were recorded unfortunately. A fetal response to maternally administered hydrocortisone appeared to be verified.
Morrison et al. 3 conducted a prospective randomized doubleblinded clinical trial in patients at risk for preterm delivery comparing no treatment (n=59) with the use of hydrocortisone 500 mg IV given four times over 36 hours (n=67). All patients had either an immature L/S ratio or were less than 34 weeks; all infants delivered within 7 days of initiation of therapy. No benefit was seen in infants who delivered less than 12 hours after initiation of treatment. Overall, the treatment group had a 9% incidence of respiratory distress syndrome (RDS) (6/67) compared to 21% in the placebo group. At weights greater than 1000 g, hydrocortisone-treated pregnancies fared better than controls, particularly if delivery occurred more than 24 hours after initiation of therapy. The small number of study participants limits this study.
A second study by Morrison and colleagues 4 compared changes in the lecithin/sphingomyelin ratios of 37 women treated with hydrocortisone 500 mg IV given four times over 36 hours versus 33 women given placebo. Gestational age at study entry ranged from 26 to 35 weeks (mean=31.2 weeks). Amniotic fluid samples were collected either by amniocentesis or from a vaginal pool before initiation of therapy; a second sample was collected at or near delivery. The time between collection of the first and second samples ranged from 9 hours to 7 days after initiation of treatment. The mean pretreatment L/S ratio was 1.32:1; following hydrocortisone therapy the mean L/S ration was 2.61:1 compared to 1.44:1 in controls. Benefit was seen 12 to 24 hours after hydrocortisone was initiated with maximal effect derived after the third dose. Limitations of the study include nonstandardized second sampling and lack of stratification by gestational age.
Zuspan et al. 9 studied changes in L/S ratio in 17 women who were either at risk of spontaneous preterm delivery (due to rupture of membranes or preterm labor) or who had maternal or fetal indications for preterm induction of labor. All patients on entry to the study had L/S ratios less than 2 to 1. Gestational age was determined retrospectively by neonatal development score (i.e., Dubowitz). The range of gestational age was 31 to 37 weeks. Patients received 1 g of hydrocortisone succinate every 6 hours for four doses. Amniocentesis was performed before treatment and between 48 and 72 hours after treatment. L/S ratios increased in 12 of 17 patients. Mean pretreatment values were 1.21 to 1 (SD 0.435) and mean posttreatment values were 2.31 to 1 (SD 1.52). This change was statistically significant with a p value less than 0.01.
Methylprednisolone and Hydrocortisone
Schmidt et al. 7 undertook a randomized double-blinded study of 92 mothers and 97 infants considered at risk for preterm labor and assigned mothers to receive one of four regimens: hydrocortisone 250 mg, methylprednisolone 125 mg, betamethasone 12 mg, or placebo. All patients received two injections separated by 24 hours. No reduction of RDS was found in the methylprednisolone and the hydrocortisone groups compared to controls; the hydrocortisone and methylprednisolone arms of the study were discontinued after 24 months. Limitations of this study include small sample size and study design.
Tauesch and colleagues 10 studied the effect of methylprednisolone on lung maturation in fetal lambs. Laparotomy was performed on 16 timed pregnant ewes at approximately day 121 of gestation. Their fetuses were injected with either saline or 40 mg of long-acting methylprednisolone. The ewes were delivered between 30 and 67 hours after injection. No difference was found in cell size, cell number distensibility, minimal surface tension or histology between the lambs who received saline and those who received methylprednisolone. When no effect was seen initially, the dose of methylprednisolone was doubled to 80 mg; again no effect was seen. The authors speculated that the configuration of methylprednisolone with the methyl group at the 6-alpha position could prevent its action on the fetal lung.
Block and coworkers 2 conducted a double-blinded study on 128 women either in preterm labor or with premature rupture of membranes. Patients were randomized to receive either 12 mg of IM betamethasone, 125 mg of IM methylprednisolone, or saline. If delivery had not occurred in 24 hours patients received a second injection of the same drug. No patient received more than two injections. Before initiation of treatment, amniotic fluid was obtained either by amniocentesis or by vaginal sample from women with ruptured membranes. Forty-seven patients had immature L/S ratios on entry to the study. All 128 infants were diagnosed as premature based on birth weight less than 2500 g and Dubowitz score less than 37 weeks. Of the patients with immature L/S ratios that received treatment, 4 of 16 in the betamethasone group, 10 of 14 in the methylprednisolone group and 12 of 17 in the saline group developed RDS. Methylprednisolone performed no better than saline. The betamethasone-treated group had a statistically significant reduction in RDS with a p<0.01.
DISCUSSION
Betamethasone and dexamethasone are the most well-studied drugs for enhancement of fetal lung maturity in women at risk for preterm delivery. A limited number of studies have been performed using hydrocortisone and methylprednisolone for fetal lung maturation. The few studies available indicate that methylprednisolone has no impact on fetal lung maturation and is not useful for this indication. 2, 7, 10, 11 Studies performed with hydrocortisone, however, showed that the drug has a more rapid onset of action and a shorter half-life than betamethasone and thus, a shorter period of action on the fetal lung. Based on the available evidence, hydrocortisone appears to be the most efficacious alternative to betamethasone and dexamethasone. The hydrocortisone regimen utilized by Morrison et al. 3 of four doses of 500 mg IV each given at 12-hour intervals (total length 36 hours) provides longer exposure of the fetal lung to the drug.
Clearly, betamethasone and dexamethasone are the preferred drugs for enhancement of fetal lung maturity in women at risk for preterm delivery. If they are not available, hydrocortisone in the dosage of 500 mg given IV every 12 h for four doses over a span of 36 hours appears to be a reasonable alternative.
